Juno Therapeutics has licensed Oxford Biomedica’s gene delivery platform in a deal that will also see the latter make vectors for clinical trials. Juno will use the technology – known as the Lentivector platform – in both its CAR-T and TCR-T development programmes. The US biotech has agreed to pay $10 million upfront as well as $86 million based on the achievement of certain developmental and regulatory milestones. Oxford Biomedica will also receive sales royalties of up to $131 million…
CureVac – the German biotech at the center of a Donald Trump acquisition rumor – has received a grant from the European Commission to expedite construction of a plant set to make a potential mRNA vaccine against coronavirus. The European Commission (EC) offered up to €80 million ($88 million) of financial support to German firm CureVac this week in its efforts to support the development and manufacture of a potential vaccine to treat the novel coronavirus (COVID-19). At the time…
Evonetix will use the funding to accelerate the development of its DNA synthesis technology platform aimed at enabling synthetic biology. We spoke to CEO Tim Brears to find out more. Cambridge, UK-based Evonetix was founded in 2015 with a focus on synthetic biology. In 2018, a Series A round raised $12.3 million and now the firm has raised $30 million in a Series B investment, led by west-coast investor Foresite Capital. The funding will be used to accelerate internal technology…